Laursen Karin Rosenkilde, Hyldgård Vibe Bolvig, Jensen Pernille Tine, Søgaard Rikke
Department of Public Health, Aarhus University, Bartholins Allé 2, 8000, Aarhus, Denmark.
Health Economics, DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, 8200, Aarhus N, Denmark.
J Robot Surg. 2018 Jun;12(2):283-294. doi: 10.1007/s11701-017-0725-x. Epub 2017 Jul 10.
The objective of this study is to examine the costs attributable to robotic-assisted laparoscopic hysterectomy from a broad healthcare sector perspective in a register-based longitudinal study. The population in this study were 7670 consecutive women undergoing hysterectomy between January 2006 and August 2013 in public hospitals in Denmark. The interventions in the study were total and radical hysterectomy performed robotic-assisted laparoscopic hysterectomy (RALH), total laparoscopic hysterectomy (TLH), or open abdominal hysterectomy (OAH). Service use in the healthcare sector was evaluated 1 year before to 1 year after the surgery. Tariffs of the activity-based remuneration system and the diagnosis-related grouping case-mix system were used for valuation of primary and secondary care, respectively. Costs attributable to RALH were estimated using a difference-in-difference analytical approach and adjusted using multivariate linear regression. The main outcome measure was costs attributable to OAH, TLH, and RALH. For benign conditions RALH generated cost savings of € 2460 (95% CI 845; 4075) per patient compared to OAH and non-significant cost savings of € 1045 (95% CI -200; 2291) when compared with TLH. In cancer patients RALH generated cost savings of 3445 (95% CI 415; 6474) per patient when compared to OAH and increased costs of € 3345 (95% CI 2348; 4342) when compared to TLH. In cancer patients undergoing radical hysterectomy, RALH generated non-significant extra costs compared to OAH. Cost consequences were primarily due to differences in the use of inpatient service. There is a cost argument for using robot technology in patients with benign disease. In patients with malignant disease, the cost argument is dependent on comparator.
本研究的目的是在一项基于登记的纵向研究中,从广泛的医疗保健部门视角审视机器人辅助腹腔镜子宫切除术的成本。本研究的对象是2006年1月至2013年8月期间在丹麦公立医院连续接受子宫切除术的7670名女性。研究中的干预措施包括机器人辅助腹腔镜子宫切除术(RALH)、全腹腔镜子宫切除术(TLH)或开腹子宫切除术(OAH)。对医疗保健部门在手术前1年至手术后1年的服务使用情况进行了评估。基于活动的薪酬系统和诊断相关分组病例组合系统的费率分别用于初级和二级护理的估值。使用差异分析方法估计RALH的成本,并通过多元线性回归进行调整。主要结局指标是OAH、TLH和RALH的成本。对于良性疾病,与OAH相比,RALH每位患者节省成本2460欧元(95%CI 845;4075),与TLH相比节省成本1045欧元(95%CI -200;2291),差异无统计学意义。在癌症患者中,与OAH相比,RALH每位患者节省成本3445欧元(95%CI 415;6474),与TLH相比成本增加3345欧元(95%CI 2348;4342)。在接受根治性子宫切除术的癌症患者中,与OAH相比,RALH产生的额外成本差异无统计学意义。成本差异主要是由于住院服务使用情况的不同。对于患有良性疾病的患者,使用机器人技术有成本优势。对于患有恶性疾病的患者,成本优势取决于比较对象。